P-glycoprotein Mediated Interactions
P-glycoprotein is a drug efflux transporter that limits oral absorption and protects the brain. Inhibiting or inducing P-gp changes the pharmacokinetics of digoxin, DOACs, and many other drugs.
## What Is P-glycoprotein?
P-glycoprotein (P-gp, also called MDR1 or ABCB1) is an ATP-dependent efflux transporter expressed in the intestinal epithelium, hepatic canalicular membrane, renal proximal tubule, and blood-brain barrier. It pumps substrates out of cells, reducing oral bioavailability, promoting biliary and renal excretion, and limiting brain penetration.
## Clinical Significance
Many drug interactions attributed solely to CYP3A4 actually involve dual CYP3A4/P-gp inhibition, since the two systems share substantial substrate overlap and are often co-regulated. Understanding P-gp's independent contribution is important for drugs primarily cleared by this transporter.
## Key P-gp Substrates
| Substrate | Clinical Impact of P-gp Changes |
|-----------|-------------------------------|
| Digoxin | Narrow therapeutic index; small level changes cause toxicity |
| Dabigatran | Major P-gp substrate; bleeding or clotting risk |
| Edoxaban | P-gp substrate; dose adjustment required |
| Colchicine | P-gp + CYP3A4 substrate; fatal toxicity possible |
| Loperamide | P-gp keeps it out of the brain; inhibition causes CNS opioid effects |
| Cyclosporine | Dual CYP3A4/P-gp substrate |
| Topotecan, vincristine | Anticancer efficacy affected |
## P-gp Inhibitors
**Strong inhibitors:**
- Cyclosporine, quinidine (prototype research inhibitor)
- Ritonavir, cobicistat
- Verapamil, dronedarone, ranolazine
- Itraconazole, ketoconazole
**Moderate inhibitors:**
- Amiodarone, clarithromycin, erythromycin
- Ticagrelor (clinically relevant with dabigatran)
### Digoxin Example
Digoxin has a narrow therapeutic index (0.5-2.0 ng/mL) and is primarily renally cleared via P-gp. Adding amiodarone, verapamil, or quinidine inhibits renal P-gp-mediated digoxin secretion, increasing serum digoxin by 50-100%. Standard practice is to halve the digoxin dose when initiating these inhibitors and monitor levels.
### Dabigatran Example
Dabigatran is the most P-gp-dependent DOAC. P-gp inhibitors increase dabigatran levels: dronedarone increases AUC by 70-100%. The FDA recommends reducing dabigatran dose to 75 mg twice daily with P-gp inhibitors in patients with moderate renal impairment, and contraindication with strong inhibitors when CrCl is below 30 mL/min.
## P-gp Inducers
- **Rifampin** — reduces digoxin levels by 30%, dabigatran AUC by 66%
- **St. John's wort** — comparable induction; digoxin levels drop significantly
- **Carbamazepine, phenytoin** — moderate P-gp induction
## Blood-Brain Barrier Implications
P-gp at the BBB limits CNS penetration of many drugs. Loperamide is a mu-opioid agonist that normally cannot enter the brain due to P-gp efflux. Co-administration with P-gp inhibitors (quinidine in research settings; inadvertent inhibition with massive doses) has caused respiratory depression and death, particularly in loperamide abuse scenarios.
## Key Takeaways
- P-gp limits oral absorption, promotes excretion, and protects the blood-brain barrier
- Digoxin levels increase 50-100% with P-gp inhibitors; halve the dose and monitor
- Dabigatran is highly P-gp-dependent; dose adjustments or avoidance with inhibitors required
- Rifampin and St. John's wort induce P-gp, reducing substrate exposure
- P-gp inhibition at the BBB can allow opioid-like drugs (loperamide) into the brain